The Apple Watch Series 12 and Ultra 4 went on sale on 18 September 2026, and in 33 countries and regions they may arrive without one of Apple’s headline health features. A footnote on Apple’s watchOS feature availability page reads: “Hypertension Notifications may not be available on Apple Watch Series 12 or Ultra 4 in your region, as additional regulatory clearances for these devices are in process.” Canada, Australia, Japan, India, Brazil and South Korea are among the places marked. Older watches from the Series 9 onward keep the feature in those same countries, so Apple Watch Series 12 hypertension alerts can be missing on the newer watch while the one it replaces still has them. Apple has not given a date for the clearances.
Where the footnote applies
Apple lists Hypertension Notifications country by country and marks 33 entries with the footnote. They are Australia, Bahrain, Brazil, Canada, Colombia, Costa Rica, Ecuador, Honduras, India, Indonesia, Israel, Japan, Kuwait, Malaysia, Moldova, the Palestinian Territories, Paraguay, Peru, Saudi Arabia, Serbia, Singapore, South Africa, South Korea, Taiwan, Thailand, Türkiye, Ukraine, the United Arab Emirates and Vietnam. The other four are Australian external territories: Christmas Island, the Cocos (Keeling) Islands, Heard and McDonald Islands and Norfolk Island.
The United States, the United Kingdom, the EU member states, Switzerland, Norway, Hong Kong, New Zealand and Chile are listed without the footnote. So a Series 12 bought there should have the feature from the start. Mexico and mainland China do not appear on the list at all, for any model.
Apple’s support article repeats the warning in slightly different words, saying clearances “for the feature for these models are in process”. The article carries a publication date of 14 September 2026, four days before the watches reached stores.
Several of these countries only got the feature in January
Apple introduced hypertension notifications in September 2025 for the Series 9 and later and the Ultra 2 and later. On 27 January 2026 it added seven countries: Australia, Malaysia, Colombia, Indonesia, South Korea, Brazil and Turkey. All seven now carry the footnote for the new models.
For an owner in Sydney or Seoul, that means the feature reached their Series 10 or Ultra 2 eight months ago, and the watch that replaces it may not offer it yet. The requirement is a regulatory one in each country, which is why the list follows national borders.
Why new watches need new clearances
Apple has not explained it beyond the phrase “additional regulatory clearances for these devices”. Health regulators usually clear a software feature together with the hardware it was tested on, and the Series 12 and Ultra 4 use a new heart rate system. Apple says it now samples heart rate every five seconds, far more often than earlier models. A new sensor and new data could plausibly need a fresh filing in each market. That is a reasonable reading of the footnote, not a reason Apple has given.
Prices did not change with the new generation. The Series 12 starts at $399 and the Ultra 4 at $799 in the United States, the same as the models they replace.
What the feature does, and what it does not
Hypertension notifications do not measure blood pressure. The watch analyses data from its optical heart sensor over 30-day evaluation periods and sends an alert if it finds a pattern consistent with chronic high blood pressure. The alert then prompts you to set up a Blood Pressure Log and take readings with a third-party cuff for seven days, so that you have real numbers to show a doctor.
Apple is careful about the limits. Its support page says the feature “is not intended to diagnose, treat, or aid in the management of hypertension” and that “not all people with hypertension receive a notification.” You must be 22 or older, not pregnant and never diagnosed with hypertension to switch it on. You also need an iPhone 11 or later with Wrist Detection turned on, and the feature is not available on any Apple Watch SE.
That eligibility list matters for the decision below. If you already have a diagnosis, the feature was never meant for you, and the footnote changes nothing. A home cuff remains the tool that gives you a number, and cuffless estimates from rings, such as the calibrated Circular Ring blood pressure trend, sit in a different category again.
If you live in one of the 33 regions
Start with Apple’s feature availability page for your country, since the footnote is the only official statement of status. If hypertension notifications are the main reason you want a Series 12 or Ultra 4, waiting costs you nothing, and your current watch keeps the feature if it is a Series 9 or later or an Ultra 2 or later.
If you buy now for other reasons, go in knowing the Health Checklist on the new watch may not show the feature for some time. Buying from Apple directly makes a change of mind easier, because Apple publishes a return window for its own stores, 14 days in the United States. Check the period for your country before you order.
A watch bought in the United States or Europe and used in Canada or Australia is a grey area. Apple’s support page asks you to make sure the feature “is available in your country or region”, and it does not say how the watch decides where you are. Relying on an imported watch to get round the footnote is a gamble.
What is still unknown
Apple has not said when the clearances will arrive, whether they will come country by country or together, or whether any other health feature on the new models is affected. It has not said what will happen to your 30-day history if you move from an older watch that has the feature to a new one that does not. The feature availability page is the place to watch. The day a country loses its footnote is the day the Series 12 becomes a like-for-like replacement there.
